College Duo Stuns America With Cancer Hack

Scientist using a microscope in a modern laboratory — Photo: Gorodenkoff / Shutterstock

A college student turned her own cancer scare into a nanotechnology breakthrough that just won national recognition.

Quick Take

Nistha Neupane, a University of Arkansas at Little Rock student, survived a benign but cancerous tumor before building a cancer-treatment startup.
She and classmate Zane Austin won the America250 “America’s Startup” national collegiate competition with their venture, NanoLit.
NanoLit uses gold nanoparticles to target chemotherapy drugs directly at tumors, sparing healthy tissue and the heart.
Neupane is heading to medical school this fall after years of hands-on cancer research funded by state grants.

A Health Scare Becomes A Research Mission

Neupane faced a tumor that turned out to be cancerous but benign, meaning it had not spread through her body. That diagnosis gave her a firsthand look at how brutal cancer treatment can be on a patient’s body. Instead of walking away shaken, she channeled the experience into a specific goal: build a treatment that attacks cancer cells without wrecking the healthy ones around them.

That mission took shape in the lab of Dr. Noureen Siraj, an associate professor of chemistry at UA Little Rock. Neupane studied how the shape of gold nanoparticles affects drug delivery, testing nanospheres and other structures to see which design best carries chemotherapy drugs to tumor sites. The work earned her a Student Undergraduate Research Fellowship grant from the Arkansas Division of Higher Education, and she won it a second year in a row.

Her research did not stay confined to a university lab. Neupane presented findings at national conferences, including gatherings of the American Chemical Society, while also focusing part of her academic work on advocacy in medicine. That combination of bench science and public-facing communication helped her pitch an idea that judges outside the university found compelling enough to fund and celebrate.

NanoLit Targets Chemotherapy’s Collateral Damage

Neupane and fellow UA Little Rock student Zane Austin built NanoLit around a direct problem: standard chemotherapy kills cancer cells but also damages healthy ones, often including the heart. Their venture, described in a university release, was designed to address the harsh side effects of chemotherapy by creating a more targeted treatment approach that reduces damage to healthy cells. The goal is heart-protective therapy specifically for breast cancer patients going through chemo.

That focus places NanoLit inside a well-established branch of cancer research. Scientists have spent two decades building drug-delivery systems meant to raise the therapeutic index of chemotherapy agents by concentrating their activity at the tumor site instead of letting them spread through the whole body. Peer-reviewed reviews describe targeted delivery as the most promising strategy for cutting chemo toxicity, with most clinical studies showing real reductions in harmful side effects.

NanoLit’s pitch won the America250 “America’s Startup” national collegiate competition, an initiative tied to the United States’ upcoming 250th anniversary. The university announcement credited the duo’s nanotechnology venture with bringing national attention to campus innovation, a notable achievement for undergraduates competing against teams from across the country.

Why The Science Still Has A Long Road Ahead

Gold nanoparticle research is not new, and that is a point in its favor. Scientists have pursued nanoparticle-based delivery for cancer therapy for years because it can lower the dose of toxic drugs that reaches healthy organs while still hitting the tumor hard. Reviews of the field describe nanomedicine as holding real promise precisely because it can target cancer cells while sparing surrounding tissue.

Turning a promising lab concept into an approved treatment is a different challenge entirely. Published reviews note that while many nanomedicine platforms enter clinical trials, only a small number have made it all the way to approved, widely used therapies. That gap between bench and bedside is well documented across the field, not unique to any single project, and it explains why most cancer nanotechnology ventures take years to mature beyond the award-winning pitch stage.

From Nepal Hospitals To Medical School

Neupane’s path toward medicine started well before NanoLit. As a junior, she spent six weeks interning at Green City Hospital in Kathmandu, Nepal, gaining direct exposure to patient care in a different health system. That international experience, paired with her chemistry research, built a resume aimed squarely at clinical practice rather than just the lab bench.

She is now headed to the University of Texas at Tyler School of Medicine as an incoming first-year medical student. Her trajectory, from a personal cancer scare to a national startup win to medical school, reflects a student who treated a frightening diagnosis as a problem to solve rather than a setback to simply survive. That kind of grit deserves recognition on its own terms, regardless of how far NanoLit eventually travels toward the clinic.

Her story also serves as a reminder that American universities, even smaller state schools like UA Little Rock, keep producing students willing to turn personal hardship into practical innovation. That spirit of self-reliance and problem-solving is worth celebrating, especially when it comes from a 20-something determined to fix a system that once put her own body through the wringer.